The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared… (NCT07456488) | Clinical Trial Compass
RecruitingPhase 2
The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group
Pakistan60 participantsStarted 2025-07-13
Plain-language summary
In this study, atropine 0.01% eye drops will be given to myopic children once at night daily for 6 months as compared to a control group to see the effect on axial length and refraction
Who can participate
Age range4 Years – 16 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Children aged 4-16 years
* Both genders
* Myopia of baseline SER of -1.00D or more
* Astigmatism less than or equal to -2.50D
* No medical history predisposing severe myopia (e.g., Marfan syndrome, Stickler syndrome, and retinopathy of prematurity), abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus, and spherophakia)
* No history of other vision-threatening ocular diseases or previous intraocular surgery.
* No current or previous use of atropine or pirenzipine, contact lenses or other forms of treatment that may affect myopia progression.
Exclusion Criteria:
* Astigmatism ≥ 2.5 D
* Anisometropia\>1 D
* Best corrected visual acuity \< 0.5 (6/12)
* Prior intraocular surgery
* Allergy to atropine eye drops
* Systemic diseases associated with myopia such as Marfan syndrome, Stickler syndrome
* History of cardiac or significant respiratory diseases
* Lack of consent for participating in the study
What they're measuring
1
Change in axial length in mm
Timeframe: 6 months
2
Change in refraction in Diopters
Timeframe: 6 months
Trial details
NCT IDNCT07456488
SponsorLiaquat National Hospital & Medical College